DOCSLIB.ORG

Abnormal Uterine Bleeding in the Adolescent Patient

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abnormal Uterine Bleeding in the Adolescent Patient ADOLESCENT GYNECOLOGY Abnormal Uterine Bleeding in the Adolescent Patient Nirupama K. DeSilva, MD Common Clinical Scenario: A 14-year-old fe- due to an immature hypotha- FOCUSPOINT male presents to your office with the complaint lamic-pituitary-ovarian (HPO) of menses “every 2 weeks” for the past few axis, causing anovulatory cy- months. She states that her periods started at cles and irregular bleeding.4 age 13, and after her first period she did not Before the diagnosis of imma- have another menses for 3 months. After her sec- ture HPO axis can be assumed, Many patients ond menstrual cycle, her periods started “hap- more serious disorders must complain of pening all the time.” She notes that menses be ruled out (Table).5,6 While menstrual problems sometimes come once a month, sometimes “skip there are numerous etiologies a month,” and lately have been coming twice a for abnormal uterine bleeding that actually fall month. Her menses last for 5 days, during which in the adolescent, this article within normal she changes 3 pads per day. She is in good will concentrate on the evalua- variations. health, with no medical problems or history of tion and management of DUB surgeries. Urine pregnancy test is negative. in the adolescent female. enstrual disorders are among the EVALUATION most common complaints of adoles- When an adolescent presents cents. This is in part because adoles- with the complaint of DUB, she should be asked cents and their families often have detailed questions about her menstrual history, Mdifficulty understanding what normal cycles or including the age at menarche and the timing, patterns of bleeding are and in part because duration, and quantity of her uterine bleeding. there is considerable menstrual cycle variabil- The presence of cramping and/or clots can be ity in the adolescent years.1 Regular ovulatory useful information as well. menstrual cycles occur every 21 to 35 days and Review of systems should address psychosocial last up to 7 days, with an average blood loss of stressors, weight changes, eating and exercise 25 to 69 mL.2 Many patients complain of men- habits, medications, and symptoms of hyperan- strual problems that actually fall within nor- drogenism. Family history of bleeding disorders mal variations. In the first year after menarche, and menstrual history is imperative, as is a sex- 50% of cycles are anovulatory, but 80% still fall ual history.7 in the normal range for duration. By the third Physical examination should include vital year of menarche, 95% of menstrual cycles fall signs and evaluate for signs of hyperandrogen- into this range.3 Charting the menstrual flow ism and bleeding. The Sexual Maturity Rating on a calendar can be helpful to clarify normal scale should be determined to be at the appro- versus abnormal cycles. Cycles that fall outside priate stage for the patient’s age. The nipples of the norm should be evaluated for underlying should be assessed for discharge. In most pa- pathology. tients, especially those who are not sexually ac- While there are multiple causes for abnormal tive, an internal pelvic exam is not necessary to uterine bleeding in adolescents, the most likely evaluate the pelvic anatomy. In such patients, cause is dysfunctional uterine bleeding (DUB) an ultrasound may be sufficient to evaluate for pelvic pathology. If a pelvic exam is absolutely Nirupama K. DeSilva, MD, is Assistant Professor, Department needed in cases of massive bleeding, trauma, of Obstetrics and Gynecology, University of Oklahoma School or suspected congenital anomolies, one can be of Community Medicine, Tulsa. performed under anesthesia. Sexually active Follow The Female Patient on and The Female Patient | VOL 35 JULY 2010 25 ADOLESCENTGYNECOLOGY Abnormal Uterine Bleeding in the Adolescent Patient TABLE. Causes of Abnormal Uterine Bleeding in the Adolescent5,6 Anovulation • Progestins (eg, Depo-Provera) Bleeding associated with pregnancy • Spironolactone • Abortion (threatened or incomplete) Ovarian failure • Ectopic Pathology involving the reproductive tract • Retained products of conception • Endometrial hyperplasia/carcinoma Coagulation defects • Endometrial polyp Congenital malformation of the uterus Systemic diseases Endometriosis • Adrenal insufficiency • Chronic renal disease Exercise-induced amenorrhea • Cushing syndrome Hyperprolactinemia • Diabetes mellitus Infections • Late-onset congenital adrenal hyperplasia • Condyloma of the cervix/vagina • Liver disease • Pelvic inflammatory disease • Polycystic ovary syndrome • Vaginitis/cervicitis (trichomonas/gonorrhea) • Systemic lupus erythematosis Medications • Thyroid abnormalities • Anticoagulants Trauma • Chemotherapy drugs • Danazol Tumor • Exogenous steroids • Ovarian cyst or tumor • Oral contraception (eg, midcycle bleeding • Sarcoma botryoides or continuous use) females should receive testing for sexually trans- antigen, and plasma VWF activity (ristocetin mitted infections. cofactor activity). Laboratory work-up of adolescents with ab- As well, in any patient with abnormal uterine normal uterine bleeding should include a preg- bleeding, thyroid function tests should be con- nancy test, regardless of whether the history sidered, as this can be a common cause of ab- reveals sexual activity. Once pregnancy has normal uterine bleeding. In patients with head- been ruled out, the practitioner should con- aches or nipple discharge, prolactin testing is sider additional lab work to rule on other diag- warranted. In those with signs of polycystic noses in the differential based on the present- ovary syndrome or insulin resistance, the practi- ing signs and symptoms. A complete blood tioner should consider appropriate lab testing, count may be helpful to evaluate for anemia. including testosterone, insulin, and glucose ACOG recommends that all patients younger levels. Evaluating the adrenal glands to look for than 18 who present with abnormal uterine abnormalities in suspected cases may be war- bleeding be screened for coagulation disor- ranted as well. ders, particularly von Willebrand disease, as this disorder has a prevalence of 1% and is the MANAGEMENT most common disorder that causes menorrha- After other diagnoses have been ruled out, the gia at menarche.1,6 Screening for such disorders management of DUB can occur as an outpatient should include a partial thromboplastin time, in the majority of cases. Occasionally, however, prothrombin time, and assessment of platelet hospitalization is required due to hemodynamic function, plasma von Willebrand factor (VWF) instability. 26 The Female Patient | VOL 35 JULY 2010 All articles are available online at www.femalepatient.com. DeSilva Mild Uterine Bleeding (Hgb >12 mg/dL) Severe Uterine Bleeding/Menorrhagia Management of mild abnormal bleeding consists (Hgb <10 mg/dL) of observation and reassurance. If hemoglobin Excessive menstrual bleeding is diagnosed as (Hgb) concentration is normal (>12 mg/dL), girls menses more often than every 21 days or bleed- with mild DUB should be asked to keep a men- ing resulting in a loss of more than 80 mL of strual calendar and can be given the option to blood.2 Menstrual flow requir- avoid treatment with hormonal therapy. They ing changes of menstrual FOCUSPOINT should follow up in 3 to 6 months, unless bleed- products every 1 to 2 hours is ing becomes more severe, in which case they considered excessive, espe- should be seen acutely. cially if the flow lasts longer Menstrual flow than 7 days.1 While it may be requiring changes Moderate Uterine Bleeding (Hgb 10-12 mg/dL) due to anovulation, this type of of menstrual Moderate DUB is characterized by moderately bleeding may be associated prolonged or frequent menses every 1 to 3 with a bleeding disorder, and products every weeks.8 Menstrual flow is moderate to heavy. work-up for this should ensue. 1 to 2 hours is con- Mild anemia (Hgb 10-12 mg/dL) is often present Hospitalization is necessary sidered excessive, but without signs of hypovolemia or hemody- for patients who are hemody- namic instability. Moderate DUB can usually be namically unstable, who have especially if the managed in the outpatient setting. The treatment low Hgb concentration (<7 mg/ flow lasts longer typically involves hormonal therapy to stabilize dL), or who have symptomatic than 7 days. endometrial proliferation and shedding. The anemia.8 Heavy active bleeding choice of agent(s) depends, to some extent, upon and Hgb lower than 10 mg/dL how heavily the patient is bleeding.9 Girls with are also considered by some to moderate DUB should be provided with iron be an indication for hospitaliza- supplementation. tion. If the Hgb is between 8 and 10 mg/dL, and There is a paucity of data from randomized the patient is hemodynamically stable, and the trials regarding the treatment of DUB in adoles- patient and family are reliable and can maintain cents. Nonetheless, there are a variety of regi- close telephone contact, home management may mens that appear to be equally effective. Pa- be possible with daily monitoring. tients who have complaints of heavier bleeding The need for blood transfusion should be in- may have a better response to oral contracep- dividualized, and it should be administered as tives (OCs) that have a combination of estrogen deemed necessary by the clinician based on and progestin rather than to progestin-only the patient’s initial blood count, amount of preparations, as estrogen provides hemostasis. bleeding, and any other comorbidities. Thus, one option is to use monophasic contra- Girls who require hospitalization
Load more

Recommended publications
  • Infertility Update
    Infertility Update George R Attia, M.D Director of IVF Program University of Texas Southwestern Medical Center at Dallas Infertility • Inability to conceive after one year of adequate unprotected intercourse (six months if the woman is over age 35) Time Required for Conception in Couples Who Will Attain Pregnancy 100 93 95 90 85 80 72 70 nt 57 60 na g 45 e 50 r P 40 % 30 25 20 10 0 1 month 2 months 3 months 6 months 1 Year 2 Year 3 ear 7% 3% 35% Male Factor 20% Tubal Factor Ov dysfunction Unexplained Others 35% 10% 10% 40% Anovulatory Tubal & Pelvic Unusual factors Unexplained 40% • Anovulation • Tubal Factor • Male • Pelvic Factor (Endometriosis, adhesion) • Unexplained • Uterine/cervical (fibroid) 10% PCOS Others 90% Ovulation • History •BBT • LH kits • Mid luteal phase Progesterone (cycle length –7) • Ultrasound • EMB (day 21-26) • Anovulation • Tubal / Pelvic Factor • Male • Unexplained • Uterine/cervical (fibroid) Tubal & Pelvic Factors • Tubal disease, PID • Tubal surgery • Pelvic adhesions • Endometriosis Tubal Factor • Tubal infertility after PID (12%, 24%, 50%) • One-half of patients who found to have tubal damage and/or pelvic adhesion have no history of antecedent disease Tubal Factor • Hysterosalpingography • Hysteroscopy / laparoscopy • Falloscopy • Anovulation • Tubal Factor • Male • Unexplained • Uterine/cervical (fibroid) Male Factor Infertility • Anatomic defects (hypospadias, Retrograde ejac.) • Genetics Causes • Trauma • Infection • Endocrine disorders •Varicocele Male Factor Infertility • Vol. > 2 ml, Conc. > 20x106,
    [Show full text]
  • Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium
    Published OnlineFirst November 15, 2017; DOI: 10.1158/1055-9965.EPI-17-0655 Research Article Cancer Epidemiology, Biomarkers Polycystic Ovary Syndrome, Oligomenorrhea, and & Prevention Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium Holly R. Harris1, Ana Babic2, Penelope M. Webb3,4, Christina M. Nagle3, Susan J. Jordan3,5, on behalf of the Australian Ovarian Cancer Study Group4; Harvey A. Risch6, Mary Anne Rossing1,7, Jennifer A. Doherty8, Marc T.Goodman9,10, Francesmary Modugno11, Roberta B. Ness12, Kirsten B. Moysich13, Susanne K. Kjær14,15, Estrid Høgdall14,16, Allan Jensen14, Joellen M. Schildkraut17, Andrew Berchuck18, Daniel W. Cramer19,20, Elisa V. Bandera21, Nicolas Wentzensen22, Joanne Kotsopoulos23, Steven A. Narod23, † Catherine M. Phelan24, , John R. McLaughlin25, Hoda Anton-Culver26, Argyrios Ziogas26, Celeste L. Pearce27,28, Anna H. Wu28, and Kathryn L. Terry19,20, on behalf of the Ovarian Cancer Association Consortium Abstract Background: Polycystic ovary syndrome (PCOS), and one of its cancer was also observed among women who reported irregular distinguishing characteristics, oligomenorrhea, have both been menstrual cycles compared with women with regular cycles (OR ¼ associated with ovarian cancer risk in some but not all studies. 0.83; 95% CI ¼ 0.76–0.89). No significant association was However, these associations have been rarely examined by observed between self-reported PCOS and invasive ovarian cancer ovarian cancer histotypes, which may explain the lack of clear risk (OR ¼ 0.87; 95% CI ¼ 0.65–1.15). There was a decreased risk associations reported in previous studies. of all individual invasive histotypes for women with menstrual Methods: We analyzed data from 14 case–control studies cycle length >35 days, but no association with serous borderline including 16,594 women with invasive ovarian cancer (n ¼ tumors (Pheterogeneity ¼ 0.006).
    [Show full text]
  • Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009†
    Human Reproduction, Vol.24, No.11 pp. 2683–2687, 2009 Advanced Access publication on October 4, 2009 doi:10.1093/humrep/dep343 SIMULTANEOUS PUBLICATION Infertility The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009† F. Zegers-Hochschild1,9, G.D. Adamson2, J. de Mouzon3, O. Ishihara4, R. Mansour5, K. Nygren6, E. Sullivan7, and S. van der Poel8 on behalf of ICMART and WHO 1Unit of Reproductive Medicine, Clinicas las Condes, Santiago, Chile 2Fertility Physicians of Northern California, Palo Alto and San Jose, California, USA 3INSERM U822, Hoˆpital de Biceˆtre, Le Kremlin Biceˆtre Cedex, Paris, France 4Saitama Medical University Hospital, Moroyama, Saitana 350-0495, JAPAN 53 Rd 161 Maadi, Cairo 11431, Egypt 6IVF Unit, Sophiahemmet Hospital, Stockholm, Sweden 7Perinatal and Reproductive Epidemiology and Research Unit, School Women’s and Children’s Health, University of New South Wales, Sydney, Australia 8Department of Reproductive Health and Research, and the Special Program of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland 9Correspondence address: Unit of Reproductive Medicine, Clinica las Condes, Lo Fontecilla, 441, Santiago, Chile. Fax: 56-2-6108167, E-mail: [email protected] background: Many definitions used in medically assisted reproduction (MAR) vary in different settings, making it difficult to standardize and compare procedures in different countries and regions. With the expansion of infertility interventions worldwide, including lower resource settings, the importance and value of a common nomenclature is critical. The objective is to develop an internationally accepted and continually updated set of definitions, which would be utilized to standardize and harmonize international data collection, and to assist in monitoring the availability, efficacy, and safety of assisted reproductive technology (ART) being practiced worldwide.
    [Show full text]
  • Diagnostic Evaluation of the Infertile Female: a Committee Opinion
    Diagnostic evaluation of the infertile female: a committee opinion Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Diagnostic evaluation for infertility in women should be conducted in a systematic, expeditious, and cost-effective manner to identify all relevant factors with initial emphasis on the least invasive methods for detection of the most common causes of infertility. The purpose of this committee opinion is to provide a critical review of the current methods and procedures for the evaluation of the infertile female, and it replaces the document of the same name, last published in 2012 (Fertil Steril 2012;98:302–7). (Fertil SterilÒ 2015;103:e44–50. Ó2015 by American Society for Reproductive Medicine.) Key Words: Infertility, oocyte, ovarian reserve, unexplained, conception Use your smartphone to scan this QR code Earn online CME credit related to this document at www.asrm.org/elearn and connect to the discussion forum for Discuss: You can discuss this article with its authors and with other ASRM members at http:// this article now.* fertstertforum.com/asrmpraccom-diagnostic-evaluation-infertile-female/ * Download a free QR code scanner by searching for “QR scanner” in your smartphone’s app store or app marketplace. diagnostic evaluation for infer- of the male partner are described in a Pregnancy history (gravidity, parity, tility is indicated for women separate document (5). Women who pregnancy outcome, and associated A who fail to achieve a successful are planning to attempt pregnancy via complications) pregnancy after 12 months or more of insemination with sperm from a known Previous methods of contraception regular unprotected intercourse (1).
    [Show full text]
  • How to Evaluate Vaginal Bleeding and Discharge
    How to Evaluate Vaginal Bleeding and Discharge Is the bleeding normal or abnormal? When does vaginal discharge reflect something as innocuous as irritation caused by a new soap? And when does it signal something more serious? The authors’ discussion of eight actual patient presentations will help you through the next differential diagnosis for a woman with vulvovaginal complaints. By Vincent Ball, MD, MAJ, USA, Diane Devita, MD, FACEP, LTC, USA, and Warren Johnson, MD, CPT, USA bnormal vaginal bleeding or discharge is typically due to either inadequate levels of estrogen one of the most common reasons women or a persistent corpus luteum. Structural causes of come to the emergency department.1,2 bleeding include leiomyomas, endometrial polyps, or Because the possible underlying causes malignancy. Infectious etiologies include pelvic in- Aare diverse, the patient’s age, key historical factors, flammatory disease (PID). Additionally, a variety of and a directed physical examination are instrumental bleeding dyscrasias involving platelet or clotting fac- in deciding on diagnosis and treatment. This article tors can complicate the normal menstrual period. Iat- will review some common case presentations of rogenic causes of vaginal bleeding include hormone nonpregnant female patients with abnormal vaginal replacement therapy, steroid hormone contraception, bleeding, inflammation, or discharge. and contraceptive intrauterine devices.3-5 Anovulatory bleeding is common in perimenar- ABNORMAL VAGINAL BLEEDING chal girls as a result of an immature hypothalamic- To ensure appropriate patient management, “Is she pituitary axis and in perimenopausal women due to pregnant?” should be the first question addressed, declining levels of estrogen. During reproductive since some vulvovaginal signs and symptoms will years, dysfunctional uterine differ in significance and urgency depending on the bleeding (DUB) is the most >>FAST TRACK<< answer.
    [Show full text]
  • Changes Before the Change1.06 MB
    Changes before the Change Perimenopausal bleeding Although some women may abruptly stop having periods leading up to the menopause, many will notice changes in patterns and irregular bleeding. Whilst this can be a natural phase in your life, it may be important to see your healthcare professional to rule out other health conditions if other worrying symptoms occur. For further information visit www.imsociety.org International Menopause Society, PO Box 751, Cornwall TR2 4WD Tel: +44 01726 884 221 Email: [email protected] Changes before the Change Perimenopausal bleeding What is menopause? Strictly defined, menopause is the last menstrual period. It defines the end of a woman’s reproductive years as her ovaries run out of eggs. Now the cells in the ovary are producing less and less hormones and menstruation eventually stops. What is perimenopause? On average, the perimenopause can last one to four years. It is the period of time preceding and just after the menopause itself. In industrialized countries, the median age of onset of the perimenopause is 47.5 years. However, this is highly variable. It is important to note that menopause itself occurs on average at age 51 and can occur between ages 45 to 55. Actually the time to one’s last menstrual period is defined as the perimenopausal transition. Often the transition can even last longer, five to seven years. What hormonal changes occur during the perimenopause? When a woman cycles, she produces two major hormones, Estrogen and Progesterone. Both of these hormones come from the cells surrounding the eggs. Estrogen is needed for the uterine lining to grow and Progesterone is produced when the egg is released at ovulation.
    [Show full text]
  • Abnormal Uterine Bleeding: a Management Algorithm
    J Am Board Fam Med: first published as 10.3122/jabfm.19.6.590 on 7 November 2006. Downloaded from EVIDENCED-BASED CLINICAL MEDICINE Abnormal Uterine Bleeding: A Management Algorithm John W. Ely, MD, MSPH, Colleen M. Kennedy, MD, MS, Elizabeth C. Clark, MD, MPH, and Noelle C. Bowdler, MD Abnormal uterine bleeding is a common problem, and its management can be complex. Because of this complexity, concise guidelines have been difficult to develop. We constructed a concise but comprehen- sive algorithm for the management of abnormal uterine bleeding between menarche and menopause that was based on a systematic review of the literature as well as the actual management of patients seen in a gynecology clinic. We started by drafting an algorithm that was based on a MEDLINE search for rel- evant reviews and original research. We compared this algorithm to the actual care provided to a ran- dom sample of 100 women with abnormal bleeding who were seen in a university gynecology clinic. Discrepancies between the algorithm and actual care were discussed during audiotaped meetings among the 4 investigators (2 family physicians and 2 gynecologists). The audiotapes were used to revise the algorithm. After 3 iterations of this process (total of 300 patients), we agreed on a final algorithm that generally followed the practices we observed, while maintaining consistency with the evidence. In clinic, the gynecologists categorized the patient’s bleeding pattern into 1 of 4 types: irregular bleeding, heavy but regular bleeding (menorrhagia), severe acute bleeding, and abnormal bleeding associated with a contraceptive method. Subsequent management involved both diagnostic and treatment interven- tions, which often occurred simultaneously.
    [Show full text]
  • Too Much, Too Little, Too Late: Abnormal Uterine Bleeding
    Too much, too little, too late: Abnormal uterine bleeding Jody Steinauer, MD, MAS July, 2015 The Questions • Too much (& too early or too late) – Differential and approach to work‐up – Does she need an endometrial biopsy (EMB)? – Does she need an ultrasound? – How do I stop peri‐menopausal bleeding? – Isn’t it due to the fibroids? • Too fast: She’s hemorrhaging—what do I do? • Too little: A quick review of amenorrhea Case 1 A 46 yo G3P2T1 reports her periods have become 1. What term describes increasingly irregular and heavy her symptoms? over the last 6‐8 months. 2. Physiologically, what Sometimes they come 2 times causes this type of per month and sometimes there bleeding pattern? are 2 months between. LMP 2 3. What is the months ago. She bleeds 10 days differential? with clots and frequently bleeds through pads to her clothes. She occasionally has hot flashes. She also has diabetes and is obese. Q1: In addition to a urine pregnancy test and TSH, which of the following is the most appropriate test to obtain at this time? 1. FSH 2. Testosterone & DHEAS 3. Serum beta‐HCG 4. Transvaginal Ultrasound (TVUS) 5. Endometrial Biopsy (EMB) Terminology: What is abnormal? • Normal: Cycle= 28 days +‐ 7 d (21‐35); Length=2‐7 days; Heaviness=self‐defined • Too little bleeding: amenorrhea or oligomenorrhea • Too much bleeding: Menorrhagia (regular timing but heavy (according to patient) OR long flow (>7 days) • Irregular bleeding: Metrorrhagia, intermenstrual or post‐ coital bleeding • Irregular and Excessive: Menometrorrhagia • Preferred term for non‐pregnant bleeding issues= Abnormal Uterine Bleeding (AUB) – Avoid “DUB” ‐ dysfunctional uterine bleeding.
    [Show full text]
  • Rare Case of Vaginal Bleeding with a Normal Vault Following Surgical Menopause”
    Downloaded from www.medrech.com “Rare case of vaginal bleeding with a normal vault following surgical menopause” ISSN No. 2394-3971 Case Report RARE CASE OF VAGINAL BLEEDING WITH A NORMAL VAULT FOLLOWING SURGICAL MENOPAUSE Lakshmi Rathna Markhani, Nidhi Saluja, Swati Mothe Department of Obstetrics and Gynaecology, Nice Hospital for Women Children and Newborn,Hyderabad,India Submitted on: December 2016 Accepted on: January 2017 For Correspondence Email ID: Abstract Post Hysterectomy Causes of bleeding include atrophic vaginitis, vaginal vault granulation, prolapsed fallopian tube, cervical stump cancer, infiltrating ovarian tumors, estrogen secreting tumors in other parts of the body and rarely carcinoma of the fallopian tube. Endometriosis of the vault sometimes can cause postmenopausal bleeding. Post Hysterectomy complications at the vault site such as a bleeding incident can be commonly observed at a short-term post-operative period. Other delayed complications often occur as a hematoma, granuloma, keloid, incision hernia and or vascular formation at the vault. Many of these complications may be accompanied with bleeding symptoms. This case report describes persistent bleeding from vaginal vault 18 months following Hysterectomy. Keywords: Surgical menopause, Vaginal bleeding, Hysterectomy. Introduction Endometriosis has been described Endometriosis is defined as the presence of previously in case reports as a rare functional endometrial glands and stroma complication associated with Laparoscopic outside the usual location in the lining of the Hysterectomy and post abdominal surgery Uterine cavity(1-3). It occurs most (scar endometriosis (6).Post Hysterectomy commonly in the gynecologic organs and complications at the vault site such as a pelvic peritoneum but may frequently bleeding incident can be commonly involve the gastrointestinal system, greater observed at a short-term post-operative omentum, and surgical scars, while it is period.
    [Show full text]
  • Oligo-Anovulation Is Not a Rarer Feature in Women with Documented Endometriosis
    Oligo-anovulation is not a rarer feature in women with documented endometriosis Pietro Santulli, M.D., Ph.D.,a,b Chloe Tran, M.D.,a Vanessa Gayet, M.D.,a Mathilde Bourdon, M.D.,a,b Chloe Maignien, M.D.,a Louis Marcellin, M.D.,a,b Khaled Pocate-Cheriet, M.D.,b Charles Chapron, M.D.,a,b and Dominique de Ziegler, M.D.a a Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hopitaux^ de Paris (AP-HP), Hopital^ Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Universite Paris Descartes, Sorbonne Paris Cite; and b Department of Development, Reproduction and Cancer, Institut Cochin, INSERM U1016, Universite Paris Descartes, Sorbonne Paris Cite, Paris, France Objective: To study the prevalence of oligo-anovulation in women suffering from endometriosis compared to that of women without endometriosis. Design: A single-center, cross-sectional study. Setting: University hospital-based research center. Patient (s): We included 354 women with histologically proven endometriosis and 474 women in whom endometriosis was surgically ruled out between 2004 and 2016. Intervention: None. Main Outcome Measure(s): Frequency of oligo-anovulation in women with endometriosis as compared to that prevailing in the disease-free reference group. Results: There was no difference in the rate of oligo-anovulation between women with endometriosis (15.0%) and the reference group (11.2%). Regarding the endometriosis phenotype, oligo-anovulation was reported in 12 (18.2%) superficial peritoneal endometriosis, 12 (10.6%) ovarian endometrioma, and 29 (16.6%) deep infiltrating endometriosis. Conclusion(s): Endometriosis should not be discounted in women presenting with oligo-anovulation.
    [Show full text]
  • Colorectal-Vaginal Fistulas: Imaging and Novel Interventional Treatment Modalities
    Journal of Clinical Medicine Review Colorectal-Vaginal Fistulas: Imaging and Novel Interventional Treatment Modalities M-Grace Knuttinen *, Johnny Yi ID , Paul Magtibay, Christina T. Miller, Sadeer Alzubaidi, Sailendra Naidu, Rahmi Oklu ID , J. Scott Kriegshauser and Winnie A. Mar ID Mayo Clinic Arizona; Phoenix, AZ 85054 USA; [email protected] (J.Y.); [email protected] (P.M.); [email protected] (C.T.M.); [email protected] (S.A.); [email protected] (S.N.); [email protected] (R.O.); [email protected] (J.S.K.); [email protected](W.A.M.) * Correspondence: [email protected]; Tel.: +480-342-1650 Received: 11 March 2018; Accepted: 16 April 2018; Published: 22 April 2018 Abstract: Colovaginal and/or rectovaginal fistulas cause significant and distressing symptoms, including vaginitis, passage of flatus/feces through the vagina, and painful skin excoriation. These fistulas can be a challenging condition to treat. Although most fistulas can be treated with surgical repair, for those patients who are not operative candidates, limited options remain. As minimally-invasive interventional techniques have evolved, the possibility of fistula occlusion has enriched the therapeutic armamentarium for the treatment of these complex patients. In order to offer optimal treatment options to these patients, it is important to understand the imaging and anatomical features which may appropriately guide the surgeon and/or interventional radiologist during pre-procedural planning. Keywords: colorectal-vaginal fistula; fistula; percutaneous fistula repair 1. Review of Current Literature on Vaginal Fistulas Vaginal fistulas account for some of the most distressing symptoms seen by clinicians today. The symptomatology of vaginal fistulas is related to the type of fistula; these include rectovaginal, anovaginal, colovaginal, enterovaginal, vesicovaginal, ureterovaginal, and urethrovaginal fistulas, with the two most common types reported as being vesicovaginal and rectovaginal [1].
    [Show full text]
  • ASCCP Clinical Practice Statement Evaluation of the Cervix in Patients with Abnormal Vaginal Bleeding Published: February 7, 2017
    ASCCP Clinical Practice Statement Evaluation of the Cervix in Patients with Abnormal Vaginal Bleeding Published: February 7, 2017 All women presenting with abnormal vaginal bleeding should receive evaluation of the cervix and vagina, which should include at minimum visual inspection (speculum exam) and palpation (bimanual exam). If cervical or vaginal lesions are noted, appropriate tissue sampling is recommended, which can include Pap testing in addition to biopsy with or without colposcopy. These recommendations concur with those of ACOG Practice Bulletin #128 and Committee Opinion #557.1,2 The purpose of this article is to remind clinicians that Pap testing, as a form of tissue sampling, can be an important part of the workup of abnormal bleeding, and can be performed even if the patient is not due for her next screening test if there is clinical concern for cancer. Due to confusion amongst clinicians that has come to our attention, we wish to highlight the distinction between recommendations for diagnosis of cervical abnormalities including cancer amongst women with abnormal bleeding and recommendations for screening for cervical cancer amongst asymptomatic women. Screening guidelines recommend Pap testing at 3 year intervals for women ages 21-29, and Pap and HPV co-testing at 5 year intervals between the ages of 30-65 (with continued Pap testing at 3 year intervals as an option). These evidence- based guidelines are designed to maximize the detection of pre-cancer and minimize colposcopies. In addition, clinical practice guidelines no longer support routine pelvic examinations for cancer screening in asymptomatic women as this has not been shown to prevent cancer deaths.3,4,5 Consequently, physicians now perform fewer pelvic exams.
    [Show full text]